Breaking News Instant updates and real-time market news.

GOOGL

Alphabet Class A

$1,106.50

-15.38 (-1.37%)

, CY

Cypress Semiconductor

$17.82

-0.075 (-0.42%)

09:11
06/03/19
06/03
09:11
06/03/19
09:11

Fly Intel: Pre-market Movers

HIGHER: Cypress (CY), up 26% after announcing Infineon (IFNNY) will acquire the company for $23.85 per share in cash, corresponding to an enterprise value of EUR9B... Humana (HUM), up 3% after confirming it will not propose a merger with Centene (CNC)... Genocea (GNCA), up 88% after announcing clinical results from its ongoing Phase 1/2a trial for GEN-009, the company's neoantigen vaccine candidate... El Paso Electric (EE), up 14% after announcing Infrastructure Investments Fund will purchase the company for $68.25 in cash per share representing an enterprise value of approximately $4.3B... Nektar (NKTR), up 4% after biomarker and clinical data from PIVOT-02 was presented at the American Society of Clinical Oncology. LOWER: Centene, down 8% after Humana disclosed that it will not propose a merger with the company... Alphabet (GOOGL), down 3% after the Wall Street Journal reported that the U.S. Department of Justice is preparing to open an investigation into Google's compliance with antitrust laws... FedEx (FDX), down 3% after Reuters reported China will investigate whether FedEx damaged the legal rights and interests of its clients after Huawei said parcels intended for it were diverted... Big Lots (BIG), down 4% after BofA/Merrill analyst Jason Haas double downgraded the stock to Underperform from Buy and cut his price target for the shares to $23 from $45... Infinera (INFN), down 4% after JPMorgan analyst Samik Chatterjee downgraded shares to Underweight from Neutral given a "heightened level of near-term and medium-term risks from the much more moderate level" of capex spending from cable customers.

GOOGL

Alphabet Class A

$1,106.50

-15.38 (-1.37%)

CY

Cypress Semiconductor

$17.82

-0.075 (-0.42%)

HUM

Humana

$244.89

-2.94 (-1.19%)

CNC

Centene

$57.72

0.73 (1.28%)

GNCA

Genocea

$5.55

1.13 (25.57%)

EE

El Paso Electric

$58.21

0.885 (1.54%)

NKTR

Nektar

$31.33

-0.82 (-2.55%)

GOOG

Alphabet

$1,103.69

-14.1 (-1.26%)

FDX

FedEx

$154.25

-3.745 (-2.37%)

BIG

Big Lots

$27.57

1.56 (6.00%)

INFN

Infinera

$3.11

-0.12 (-3.72%)

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 12

    Jun

  • 12

    Jun

  • 14

    Jun

  • 19

    Jun

  • 19

    Jun

  • 24

    Jun

  • 25

    Jun

  • 10

    Jul

  • 23

    Jul

  • 27

    Oct

  • 13

    Nov

GOOGL Alphabet Class A
$1,106.50

-15.38 (-1.37%)

05/29/19
CHRS
05/29/19
INITIATION
CHRS
Hold
Alphabet Class A initiated with a Hold at China Renaissance
China Renaissance analyst Ella Ji initiated Alphabet with a Hold and $1,270 price target telling investors to wait for a better stock opportunity. The analyst expects YouTube to experience some near-term volatility as it addresses safety and privacy.
05/29/19
05/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN), Facebook (FB), and Twitter (TWTR) were initiated with a Buy at Pivotal Research, while Alphabet (GOOG, GOOGL), Pinterest (PINS), and Snap (SNAP) were initiated with a Hold. 2. Anchiano Therapeutics (ANCN) initiated with an Outperform at Baird. 3. Slack Technologies (WORK) initiated with a Neutral at DA Davidson. 4. National Vision (EYE) initiated with a Buy at Berenberg. 5. IMV Inc. (IMV) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/19
PIVT
05/29/19
INITIATION
Target $1250
PIVT
Hold
Alphabet initiated with a Hold at Pivotal Research
Pivotal Research analyst Michael Levine started Alphabet with a Hold rating and $1,250 price target. Lacking expansion of margins or greater disclosure, the shares are unlikely to re-rate higher and will likely always be "cheap," Levine tells investors in a research note.
06/03/19
BOFA
06/03/19
NO CHANGE
Target $1350
BOFA
Buy
DOJ's Google probe could embolden critics of tech giants, says BofA/Merrill
After the Wall Street Journal reported late Friday that the U.S. Department of Justice is preparing to open an investigation into Google's (GOOG, GOOGL) compliance with antitrust laws, BofA/Merrill analyst Justin Post said that while FTC commissioners have voted in the past not to pursue a lawsuit and possible breakup of Google, the current climate "is somewhat different." In a research note to investors, Post says antitrust probes are "difficult to predict," and that if the DOJ moves ahead, an investigation would likely embolden critics of Facebook (FB), Amazon (AMZN) and other tech giants as well, causing rhetoric to heat up during the 2020 election year. Potential implications for Google could include new regulations on business practices or an antitrust investigation leading to a breakup, but to break up Google, the DOJ would likely have to file a lawsuit and convince judges that Google has undermined competition. Post has a Buy rating and $1,350 price target on shares of Google parent Alphabet.
CY Cypress Semiconductor
$17.82

-0.075 (-0.42%)

05/30/19
MSCO
05/30/19
UPGRADE
Target $15.5
MSCO
Equal Weight
Cypress Semiconductor upgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley analyst Craig Hettenbach upgraded Cypress Semiconductor to Equal Weight from Underweight and raised his price target for the shares to $15.50 from $11.50 following press reports indicating that the company is exploring strategic options. His new bull case value of $21 brings his valuation for the connectivity business in-line with the multiple NXP Semiconductors (NXPI) is paying for Marvell's (MRVL) connectivity business, but Hettenbach noted that if fundamentals deteriorate further and a deal does not take place, the stock could trade back down toward $11, which is his new bear case valuation.
05/30/19
RHCO
05/30/19
NO CHANGE
Target $17
RHCO
Hold
Cypress Semiconductor takeout valuation 'priced in', says SunTrust
SunTrust analyst William Stein kept his Hold rating and $17 price target on Cypress Semiconductor, saying that although the company received a takeout offer yesterday, he sees the potential deal valuation as "mostly priced in." The analyst estimates a $19 per share takeout offer based on the valuation of the recent transactions in the semiconductor industry, which is not enough to warrant M&A speculation premium.
05/30/19
MZHO
05/30/19
NO CHANGE
Target $18
MZHO
Buy
Cypress Semiconductor an attractive takeover target, says Mizuho
After Bloomberg reported yesterday that Cypress Semiconductor is potentially looking into a sale after receiving takeover interest, Mizuho analyst Vijay Rakesh says the company's long-term roadmap in "higher-growth" Automotive, Industrial and Internet of Things markets, along with improving gross margin and a "modest" valuation, make it an attractive takeover target. The analyst, however, believes there could be regulatory hurdles globally with any possible deal. He keeps a Buy rating on Cypress Semiconductor shares with an $18 price target.
05/30/19
05/30/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Neutral at Goldman Sachs with analyst Richard Ramsden saying he sees a "realistic path" to a 13% return on tangible common equity in 2020 for Citi, or 100 basis points ahead of market expectations, which he notes is not contingent on either higher interest rates or strengthening global growth trends. 2. Comcast (CMCSA) upgraded to Buy from Neutral at Guggenheim with analyst Mike McCormack saying the company's successful pivot from primarily a video distributor to a connectivity company "has been fairly smooth." 3. Zynga (ZNGA) upgraded to Overweight from Equal Weight at Stephens with analyst Jeff Cohen saying the continued acceleration of recent acquisitions and the fact that Social Casino could be poised for a second half re-acceleration give him additional confidence in Zynga's live service portfolio. 4. Penumbra (PEN) upgraded to Overweight from Neutral at JPMorgan with analyst Robert Marcus saying the Street is overly focused on competitive entrants to the stroke aspiration market. 5. Cypress Semiconductor (CY) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Craig Hettenbach citing press reports indicating that the company is exploring strategic options. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HUM Humana
$244.89

-2.94 (-1.19%)

05/10/19
05/10/19
UPGRADE

Citi upgrades Anthem, Centene, UnitedHealth to Buy after 'extreme' selloff
Citi analyst Ralph Giacobbe upgraded Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) to Buy from Neutral while maintaining Buy ratings on Cigna (CI) and Humana (HUM). The magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone," Giacobbe tells investors in a research note. The analyst sees favorable risk/rewards in the sector and does not subscribe to the view of a continued "overhang" and "uncertainty." Instead, Giacobbe expects a share recovery as "more realistic views prevail and investors become more numb to the low-likelihood headlines and political rhetoric of single payor."
05/07/19
SBSH
05/07/19
NO CHANGE
SBSH
Citi sees low likelihood of Centene walking from WellCare deal
Amid reports suggesting shareholders could challenge Centene's (CNC) acquisition of WellCare (WCG), and Humana (HUM) possibly being interested in a takeover of Centene if the WellCare deal was dropped, Citi analyst Ralph Giacobbe says he's be surprised to see the deal unravel. Further, he'd be equally surprised to see Humana come over the top for Centene after its Medicaid win in Florida and recent commentary citing optimism in its organic direction. That said, there is a scarcity of Medicaid assets, and Humana has discussed its interest in dual and other higher acuity Medicaid populations, Giacobbe tells investors in a research note. Nonetheless, the analyst ultimately sees a low likelihood of Centene walking from the WellCare deal.
05/02/19
FBCO
05/02/19
NO CHANGE
Target $315
FBCO
Outperform
Humana price target lowered to $315 from $352 at Credit Suisse
Credit Suisse analyst A.J. Rice lowered his price target for Humana to $315 from $352 following quarterly results given macro noise. The analyst reiterates an Outperform rating on the shares.
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Move lower in managed care stocks appears overdone, says Cowen
Cowen analyst Charles Rhyee lowered his target multiple for the managed care group slightly from recent historical levels, but said he believes the recent weakness in the space on concerns around "Medicare for All," the rebate rule and the Texas ACA decision appears overdone. The discount for managed care stocks relative to the broader market has risen to a multi-year high, but he argues that underlying market fundamentals are stronger than in the pre-ACA era and Rhyee contends that there is "still plenty of growth left" in the managed care space, particularly in government-sponsored business. Stocks in the group include Anthem (ANTM), Cigna (CI), Centene (CNC), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
CNC Centene
$57.72

0.73 (1.28%)

05/10/19
05/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. 3D Systems (DDD) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster noting the stock is down 25% this week after posting "lackluster" Q1 results. 2. Jones Lang LaSalle (JLL) upgraded to Buy from Neutral at Goldman Sachs with analyst Andrew Rosivach saying the company's earnings declined in Q1 due to tough comps, but this should reverse quickly. 3. Ford (F) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy stating the company's earnings are starting to hit a "sustainable inflection" due to favorable product cadence in the North America market and its restructuring efforts. 4. Whirlpool (WHR) upgraded to Buy from Neutral at Longbow with analyst David MacGregor seeing earnings upside from better than expected North American margin performance, a "gradually improving" environment in the EMEA and a favorable cyclical turn in Latin America. 5. Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) upgraded to Buy from Neutral at Citi with analyst Ralph Giacobbe the magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/03/19
BMOC
06/03/19
DOWNGRADE
Target $304
BMOC
Market Perform
WellCare downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Matt Borsch downgraded WellCare Health Plans (WCG) to Market Perform from Outperform with an unchanged price target of $304. The analyst sees Centene (CNC) as the better stock to own ahead of the pending merger. There is also the possibility of deal failure, which would leave a standalone investment in WellCare that would probably include less takeout premium than prevailed pre-merger, Borsch tells investors in a research note.
GNCA Genocea
$5.55

1.13 (25.57%)

02/28/19
HCWC
02/28/19
NO CHANGE
Target $5.75
HCWC
Buy
Genocea price target raised on higher GEN-009 odds of success at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated his Buy rating on Genocea Biosciences and raised his price target to $5.75 from $5.00 after increasing his projected chance of success for GEN-009 to 15% from 10% based on the "increasingly strong profile" of the ATLAS platform, as demonstrated most recently at SITC 2018. He also adjusted the share count to account for a recent equity raise and projected impacted from a second tranche of this raise. Pantginis keeps a Buy rating on Genocea.
06/03/19
HCWC
06/03/19
NO CHANGE
Target $42
HCWC
Buy
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Genocea Biosciences to $42 from $5.75 after the company present immunological data from the ongoing Phase 1/2a study with GEN-009. With these data, "ATLAS is now squarely thrust into the neoantigen fray with potentially superior data compared to comps that use algorithm approaches," Pantginis tells investors in a research note. He keeps a Buy rating on shares of Genocea.
EE El Paso Electric
$58.21

0.885 (1.54%)

07/20/18
MZHO
07/20/18
NO CHANGE
Target $58
MZHO
Neutral
El Paso Electric an attractive takeout candidate, says Mizuho
Mizuho analyst Paul Fremont views El Paso Electric as an attractive takeout candidate given the lack of a holding company, above average utility load growth in the company's largest service territory and need for equity issuance in the 2019/2020 time period. In a research note titled "What's Next for EE?," Fremont keeps a Neutral rating on the shares with a $58 price target.
03/04/19
WILL
03/04/19
UPGRADE
WILL
Hold
El Paso Electric upgraded to Hold from Sell at Williams Capital
06/11/18
WILL
06/11/18
DOWNGRADE
WILL
Sell
El Paso Electric downgraded to Sell from Hold at Williams Capital
NKTR Nektar
$31.33

-0.82 (-2.55%)

05/24/19
MZHO
05/24/19
NO CHANGE
Target $81
MZHO
Buy
Mizuho reiterates $81 price target on Nektar after management meetings
Mizuho analyst Difei Yang reiterates a Buy rating on Nektar Therapeutics with an $81 price target after hosting investor meetings with management. Investors remain focused on NKTR-214, says the analyst, who remains encouraged by the available data to date from Pivot across several indications. Yang admits, however, that Phase III readouts will be needed to confirm her view on NKTR-214. In the meantime, the upcoming data updates at ASCO for melanoma and ESMO for non-small-cell lung carcinoma could be catalysts for Nektar shares, Yang tells investors in a research note.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $100
PIPR
Overweight
Nektar update at ASCO likely to be positive, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren keeps an Overweight rating on Nektar Therapeutics with a $100 price target followign the company's Q1 results. The analyst looks forward to the melanoma Pivot-02 cohort update at the American Society of Clinical Oncology meeting. He believes the update is likely to be positive.
06/02/19
PIPR
06/02/19
NO CHANGE
Target $100
PIPR
Overweight
Nektar should be up on data from Bempeg CRR in melanoma, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $100 price target on Nektar, and believes shares should be up significantly on Monday following updated data from the bempegaldesleukin + nivo PIVOT-02 melanoma cohort. The increase in complete response rate from 24% to 34% at just beyond 12 months is more than the analyst and investors were anticipating and "the waterfall plot is like nothing [he has] ever seen in solid tumors." Ultimately, Van Buren believes the high quality of responses and the ability to maintain patients on therapy is contributing to robust durability, which increases his confidence in the ultimate outcome of the Phase III trial which will have a final mPFS evaluation around Q3 of 2020.
03/15/19
LEER
03/15/19
INITIATION
Target $38
LEER
Market Perform
Nektar initiated with a Market Perform at SVB Leerink
SVB Leerink initiated Nektar with a Market Perform and $38 price target.
GOOG Alphabet
$1,103.69

-14.1 (-1.26%)

05/20/19
CHLM
05/20/19
DOWNGRADE
Target $35
CHLM
Hold
Cray downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Chad Bennett downgraded Cray (CRAY) to Hold from Buy and lowered his price target on the shares to $35 from $36 after HP Enterprise (HPE) announced that it has entered into an agreement to purchase the company for $35.00 per share in cash, totaling $1.3B net of cash. The analyst believes the possibility of another buyer coming in over the top is fairly low, but notes that the price is "too low" based on the opportunities Cray has in front of it over the next few years. Furthermore, Bennett believes there would be a number of interested parties in Cray including Microsoft (MSFT), Dell (DELL), Intel (INTC), Alphabet (GOOG), Amazon (AMZN), and potentially IBM (IBM).
FDX FedEx
$154.25

-3.745 (-2.37%)

04/26/19
UBSW
04/26/19
DOWNGRADE
UBSW
Sell
FedEx downgraded to Sell from Neutral at UBS
04/26/19
04/26/19
DOWNGRADE
Target $161

Sell
FedEx downgraded to Sell from Neutral at UBS
As previously reported, UBS analyst Thomas Wadewitz downgraded FedEx to Sell and lowered his price target to $161 from $171. The analyst says that the stock is still up 17% year-to-date after falling 4.5% yesterday and sees risk/reward on the shares as "negative", with risk to its earnings from Ground margin compression and Express Europe / TNT integration challenges that are "likely to persist."
05/17/19
MSCO
05/17/19
NO CHANGE
Target $148
MSCO
Equal Weight
Morgan Stanley sees 80% odds of FedEx trading down after earnings, guidance
Morgan Stanley analyst Ravi Shanker is cautious on FedEx shares ahead of the company's Q4 report on June 25, along with which he believes the company is likely to issue FY20 guidance. Though the Q4 results "will be important," Shankar, who is expecting a miss, believes the stock will most likely react to guidance. He puts 50% odds that the company issues FY20 EPS guidance of about $16 ex-TNT costs, which compares to current consensus of $16.76. In this scenario, Shankar sees about 7% downside for the stock. He sees a 30% chance of FY20 EPS guidance of close to $15, in which case he sees about 13% downside for FedEx shares. Shanker attributes 20% odds that FedEx issues FY20 EPS guidance of close to $17, in which case he predicts about 4% upside to see the stock trade near $180 per share. Ahead of the report, Shanker keeps an Equal Weight rating and $148 price target on FedEx shares.
05/13/19
COWN
05/13/19
NO CHANGE
Target $230
COWN
Outperform
Recent FedEx weakness creates buying opportunity, says Cowen
Cowen analyst Helane Becker says the recent weakness in FedEx shares creates a buying opportunity, telling investors in a research note that she believes FedEx will see improving margins over the next few years as it benefits from cost reductions in the business. Becker expects FedEx to offer a voluntary retirement program to international employees this year and adds that it is seeing strong retail and e-commerce business, but weaker trends in industrial production. She maintains an Outperform rating and $230 price target.
BIG Big Lots
$27.57

1.56 (6.00%)

05/24/19
05/24/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Avon Products (AVP) downgraded to Neutral from Buy at DA Davidson. 2. SQM (SQM) downgraded to Market Perform from Outperform at BMO Capital with analyst Joel Jackson saying a lithium rebound or a bottoming in sentiment may take longer and that the company's earnings trajectory no longer warrants a bullish outlook. 3. Lennox (LII) downgraded to Sell from Neutral at UBS with analyst Damian Karas saying the company is trading at a "peak multiple on peak growth." 4. Weibo (WB) downgraded to Reduce from Hold at HSBC. 5. Big Lots (BIG) downgraded to Neutral from Overweight at Piper Jaffray with analyst Peter Keith saying the downgrade is based on risk to first half of 2019 estimates as well as ongoing tariff concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/19
PIPR
05/24/19
DOWNGRADE
Target $31
PIPR
Neutral
Big Lots downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Peter Keith downgraded Big Lots to Neutral from Overweight and lowered his price target for the shares to $31 from $44. The analyst says the downgrade is based on risk to first half of 2019 estimates as well as ongoing tariff concerns. The analyst believes Big Lots' Q1 was "in-line at best" and that Q2 "appears to have stepped up markdown activity." On tariffs, Big Lots imports 21% of sales from China with a majority now getting tariffed at 25%, Keith tells investors in a research note.
06/03/19
RAJA
06/03/19
NO CHANGE
Target $40
RAJA
Outperform
Big Lots estimates for Q2, FY raised at Raymond James
Raymond James analyst Dan Wewer reiterated an Outperform rating and $40 price target on Big Lots following the company's quarterly earnings report. In a research note to investors, Wewer says Big Lots is pursuing a number of promising initiatives that are beginning to benefit the company's top-line growth, but believes rising expenses tied to these initiatives will pressure EBIT and EPS for a second consecutive year. He raised his Q2 EPS forecast to 39c from 37c, in line with management's guidance, and raised his FY19 EPS outlook to $3.84 from $3.75, at the high end of management's revised guidance.
06/03/19
BOFA
06/03/19
DOWNGRADE
Target $23
BOFA
Underperform
Big Lots downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Jason Haas double downgraded Big Lots to Underperform from Buy and cut his price target for the shares to $23 from $45. The company's outlook for the rest of the year may be too optimistic and could be cut further, Haas tells investors in a research note. The analyst believes shares of Big Lots "will continue to struggle" until consistent improvement in earnings growth is demonstrated.
INFN Infinera
$3.11

-0.12 (-3.72%)

03/28/19
UBSW
03/28/19
NO CHANGE
Target $64
UBSW
Buy
Acacia Communications price target raised to $64 from $56 at UBS
UBS analyst Tejas Venkatesh raised his price target on Acacia Communications (ACIA) to $64 and kept his Buy rating, citing his increased confidence in the company's growth. The analyst points to the company's "concurrent product cycles" being in the early stages, its rising cloud market content, and its "new data center interconnect customers like Cisco (CSCO) and Infinera (INFN)". Venkatesh contends that Acacia Communications can achieve 2019 EPS of $1.80 vs. the current consensus of $1.50.
06/03/19
JPMS
06/03/19
DOWNGRADE
JPMS
Underweight
Infinera downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Samik Chatterjee downgraded Infinera to Underweight from Neutral.
06/03/19
JPMS
06/03/19
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades Infinera to Underweight on slowing cable spending
JPMorgan analyst Samik Chatterjee downgraded Infinera to Underweight from Neutral without a price target. The analyst sees a "heightened level of near-term and medium-term risks from the much more moderate level" of capex spending from cable customers. This is in addition to the already existing long-term risks relative to the acquisition, Chatterjee tells investors in a research note.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $69
PIPR
Overweight
Fabrinet target raised to $69 on 'impressive' results at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target for Fabrinet (FN) to $69 from $67 saying the company reported "impressive" March quarter results with revenue and earnings "comfortably" beating consensus expectations. Demand for telco optics remained strong in the quarter and the company is now turning modestly more upbeat regarding second half of the year strength for datacom optics, Jensen tells investors in a research note. Further, Fabrinet also announced a material win with Infinera (INFN), adds the analyst. He reiterates an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/18/19
11/18
11:17
11/18/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/18/19
11/18
11:16
11/18/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Chair Powell met with President Trump and Treasury Secretary Mnuchin »

Chair Powell met with…

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

LK

Luckin Coffee

$28.78

1.72 (6.36%)

11:09
11/18/19
11/18
11:09
11/18/19
11:09
Options
Heavy option volume in Luckin Coffee as display caffeine jitters »

Heavy option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

PTON

Peloton

$28.40

1.12 (4.11%)

11:05
11/18/19
11/18
11:05
11/18/19
11:05
Options
Peloton Interactive call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BA

Boeing

$373.21

1.66 (0.45%)

11:03
11/18/19
11/18
11:03
11/18/19
11:03
Hot Stocks
Boeing 'strongly disagrees' with OIG report conclusions about CST-100 Starliner »

In response to the Nov.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRP

TC Energy

$51.43

0.05 (0.10%)

11:00
11/18/19
11/18
11:00
11/18/19
11:00
Conference/Events
TC Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

SPY

SPDR S&P 500 ETF Trust

$311.27

-0.56 (-0.18%)

, SPX

S&P 500

$0.00

(0.00%)

10:53
11/18/19
11/18
10:53
11/18/19
10:53
General news
Trump says negative rates, easing discussed in 'very good' meeting with Powell »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$311.27

-0.56 (-0.18%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$14.66

-0.665 (-4.34%)

10:50
11/18/19
11/18
10:50
11/18/19
10:50
Options
Bad trip for Canopy put seller after 10day 30% slide »

Bad trip for Canopy put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LTS

Ladenburg Thalmann

$3.48

(0.00%)

10:49
11/18/19
11/18
10:49
11/18/19
10:49
Downgrade
Ladenburg Thalmann rating change  »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$29.33

0.08 (0.27%)

10:45
11/18/19
11/18
10:45
11/18/19
10:45
Options
Twitter call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

10:45
11/18/19
11/18
10:45
11/18/19
10:45
General news
FX Action: USD-CAD »

FX Action: USD-CAD was…

AMRN

Amarin

$23.72

-0.275 (-1.15%)

10:44
11/18/19
11/18
10:44
11/18/19
10:44
Recommendations
Amarin analyst commentary  »

Roth says Amarin's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 28

    Dec

XRX

Xerox

$38.61

-0.335 (-0.86%)

, HPQ

HP Inc.

$19.97

-0.2 (-0.99%)

10:34
11/18/19
11/18
10:34
11/18/19
10:34
On The Fly
Deutsche Bank sees 'openness' to possible deal in HP rejection of Xerox offer »

HP Inc (HPQ) announced…

XRX

Xerox

$38.61

-0.335 (-0.86%)

HPQ

HP Inc.

$19.97

-0.2 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.25

-0.58 (-0.19%)

10:34
11/18/19
11/18
10:34
11/18/19
10:34
General news
Fed Chair Powell met with Trump, did not talk monetary policy expectations »

The Federal Reserve said…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$311.25

-0.58 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$14.52

0.59 (4.24%)

10:30
11/18/19
11/18
10:30
11/18/19
10:30
Hot Stocks
Breaking Hot Stocks news story on Snap »

Snap up 4% to $14.47…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SNAP

Snap

$14.53

0.595 (4.27%)

10:30
11/18/19
11/18
10:30
11/18/19
10:30
Hot Stocks
Snap CEO says spectacles unlikely to replace phones »

Evan Spiegel is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

RVLV

Revolve Group

$15.06

-0.4 (-2.59%)

10:30
11/18/19
11/18
10:30
11/18/19
10:30
Options
Put bomber doubles position in online fashion retailer Revolve Group »

Put bomber doubles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$14.51

0.58 (4.16%)

10:29
11/18/19
11/18
10:29
11/18/19
10:29
Hot Stocks
Snap CEO says likely 10 years before spectacles are made for all day wear »

Evan Spiegel is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SNAP

Snap

$14.52

0.59 (4.24%)

10:28
11/18/19
11/18
10:28
11/18/19
10:28
Hot Stocks
Snap CEO says spectacles will take time to get to ubiquity »

Evan Spiegel is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SNAP

Snap

$14.52

0.59 (4.24%)

10:27
11/18/19
11/18
10:27
11/18/19
10:27
Hot Stocks
Snap CEO says maps will be more personal in the future »

Evan Spiegel is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AMRN

Amarin

$23.84

-0.15 (-0.63%)

, NFLX

Netflix

$301.26

6.36 (2.16%)

10:27
11/18/19
11/18
10:27
11/18/19
10:27
On The Fly
Splunk upgrade, Amarin downgrade among today's top calls on Wall Street »

Check out today's top…

AMRN

Amarin

$23.84

-0.15 (-0.63%)

NFLX

Netflix

$301.26

6.36 (2.16%)

SPLK

Splunk

$121.73

2.58 (2.17%)

WDAY

Workday

$163.83

-2.1 (-1.27%)

VSAT

ViaSat

$74.80

2.94 (4.09%)

DIS

Disney

$146.14

1.51 (1.04%)

FIVE

Five Below

$122.01

2.41 (2.02%)

DG

Dollar General

$159.85

-0.29 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

  • 21

    Nov

  • 03

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 28

    Dec

SNAP

Snap

$14.55

0.62 (4.45%)

10:26
11/18/19
11/18
10:26
11/18/19
10:26
Hot Stocks
Snap CEO sees 'huge opportunity' around maps »

Evan Spiegel is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.